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Abstract
Background: RalA and RalB are multifuntional GTPases involved in a variety of cellular processes including proliferation,
oncogenic transformation and membrane trafficking. Here we investigated the mechanisms leading to activation of Ral
proteins in pancreatic b-cells and analyzed the impact on different steps of the insulin-secretory process.
Methodology/Principal Findings: We found that RalA is the predominant isoform expressed in pancreatic islets and insulin-
secreting cell lines. Silencing of this GTPase in INS-1E cells by RNA interference led to a decrease in secretagogue-induced
insulin release. Real-time measurements by fluorescence resonance energy transfer revealed that RalA activation in
response to secretagogues occurs within 3–5 min and reaches a plateau after 10–15 min. The activation of the GTPase is
triggered by increases in intracellular Ca
2+ and cAMP and is prevented by the L-type voltage-gated Ca
2+ channel blocker
Nifedipine and by the protein kinase A inhibitor H89. Defective insulin release in cells lacking RalA is associated with a
decrease in the secretory granules docked at the plasma membrane detected by Total Internal Reflection Fluorescence
microscopy and with a strong impairment in Phospholipase D1 activation in response to secretagogues. RalA was found to
be activated by RalGDS and to be severely hampered upon silencing of this GDP/GTP exchange factor. Accordingly, INS-1E
cells lacking RalGDS displayed a reduction in hormone secretion induced by secretagogues and in the number of insulin-
containing granules docked at the plasma membrane.
Conclusions/Significance: Taken together, our data indicate that RalA activation elicited by the exchange factor RalGDS in
response to a rise in intracellular Ca
2+ and cAMP controls hormone release from pancreatic b-cell by coordinating the
execution of different events in the secretory pathway.
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Introduction
Insulin secretion from pancreatic b-cells is essential to maintain
tight control of blood glucose levels [1]. Defects in this process can
lead to chronic hyperglycaemia and to the development of
diabetes mellitus. In b-cells, the increase in intracellular ATP/
ADP ratio resulting from glucose metabolism causes closure of
ATP-sensitive K
+-channels and membrane depolarization [1].
This triggers opening of voltage-gated Ca
2+ channels and elevation
of intracellular Ca
2+ concentrations ([Ca
2+]i). The increase in
[Ca
2+]i is both necessary and sufficient to elicit an initial burst of
insulin exocytosis, mediated by fusion of insulin granules docked at
the plasma membrane. [Ca
2+]i elevation is also necessary for a
second, long-lasting phase of insulin exocytosis involving mobili-
zation of secretory granules from a reserve pool. In this case,
secretion is sustained by mitochondrial signals generated from
glucose metabolism. Glucose is the main stimulus for insulin
release but the secretory process can be finely tuned by second
messengers such as cAMP and diacylglycerol that are generated in
response to changes in the concentrations of nutrients, hormones
and neurotransmitters. Despite recent progress in the identifica-
tion of the components of the molecular machinery driving insulin
exocytosis, the precise mechanisms through which second
messenger generation is coupled to the activation of the secretory
process are still poorly understood.
Recently, the GTPase RalA was found to be a key regulator of
the secretory process of pancreatic b-cells [2]. However, in this
study, neither the mechanisms leading to the activation of RalA in
b-cells nor the precise events through which the GTPase controls
theexocytoticprocessweredetermined.RalA and RalBshare about
85% amino acid sequence identity and form a distinct subgroup of
Ras-related monomeric GTPases. The two isoforms display a
distinct tissue distribution and are involved in a variety of cellular
processes including gene expression, cell migration, cell prolifera-
tion, oncogenic transformation and membrane trafficking [3,4]. As
is the case for other GTPases, activation of Ral proteins occurs via
interaction with guanine nucleotide exchange factors (GEFs), which
promote replacement of GDP for GTP. Many Ral-GEFs, such as
RalGDS, Rlf/Rgl2, Rgl, RPM and Rgr, contain a Ras-binding
domain and become activated upon interaction with the GTP-
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elevation of [Ca
2+]i through a Ras-independent mechanism [7]. In
this case, Ral activation occurs via binding of the Ca
2+ sensor
calmodulin to the C-terminal domain of the GTPases [8]. Once
activated, RalA and RalB accomplish their multiple functions by
interacting with distinct downstream effectors [9]. Ral GTPases can
control exocytosis by regulating the assembly of the exocyst [10,11],
a multiprotein complex initially identified in a genetic dissection of
the yeast secretory pathway [12]. In mammals, the exocyst complex
is required prior the formation of the SNARE complex and the
fusion of secretory vesicles with the plasma membrane [13].
Assembly of the exocyst complex is required for the docking of
insulin-containing secretory granules with the plasma membrane of
b-cells [14]. An alternative mechanism through which Ral GTPases
can affect vesicular transport is linked to their capacity to activate
phospholipase D1 (PLD1), a key regulatory enzyme that plays an
important role in membrane trafficking and cytoskeleton dynamics
[15]. The formation of phosphatidic acid catalyzed by PLD1 is
believed to favour the curvature of phospholipid membranes and to
facilitate the fusion of secretory vesicles with the plasma membrane.
Indeed, RalA-mediated activation of PLD1 was shown to be
required for exocytosis of neuroendocrine cells [16]. Since PLD1 is
known to play an important role in insulin secretion [17,18], a
similar mechanism could potentially underlie also the effect of RalA
in pancreatic b-cells.
In this study, we used a combination of biochemical and
imaging techniques to investigate the signalling pathways leading
to RalA activation in pancreatic b-cells and to determine the
mechanisms through which this GTPase controls insulin exocy-
tosis. Our data show that RalA activation is mediated by the
exchange factor RalGDS and is triggered by increases in [Ca
2+]i
and cAMP. Silencing of RalA by RNA interference (RNAi)
resulted in a decrease in insulin secretion that was associated with
a reduced number of secretory granules docked at the plasma
membrane and a diminished activation of PLD1 in response to
secretagogues.
Results
We first determined which Ral isoform is expressed in
pancreatic b-cells. RalA was readily detected in the insulin-
secreting cell lines INS-1E and MIN6 as well as in mouse and
human pancreatic islets (Fig. 1A). INS-1E cells and, to a much
lesser extent, MIN6 cells were found to express small amounts of
RalB but this isoform was undetectable in mouse and human
pancreatic islets. These findings are unlikely to reflect differences
in the affinities between RalA and RalB antibodies. Indeed, the
RalB antibody readily detected the protein in insulin-secreting
cells overexpressing the GTPases (Figure S1). Moreover, RalA and
RalB mRNA levels assessed by RT-PCR analysis mirrored the
differences observed by Western blotting and showed that RalA is
Figure 1. Expression of RalA in insulinoma cell lines and pancreatic islets and effect of RalA knockdown on hormone secretion. A)
Aliquots (20 mg of proteins) of homogenates of INS-1E and MIN6 cell lines, as well as isolated mouse and human pancreatic islets were analyzed by
Western blotting using antibodies against RalA, RalB or actin (internal control). B) Total RNAs extracted from INS-1E and MIN6 cell lines, as well as
from freshly isolated rat pancreatic islets were analyzed by RT-PCR using primers specific for RalA or RalB. The PCR reactions yielded one single band
of the expected size. C) INS-1E cells were transiently transfected either with an empty vector or with a plasmid driving the expression of a shRNA
specifically directed against RalA (shRalA). Three days after transfection, the levels of the GTPase and of actin were assessed by Western blotting. D)
INS-1E cells were transiently transfected with a plasmid encoding hGH (Control) or with a plasmid driving the expression of both hGH and shRalA.
Three days after transfection, the cells were preincubated for 30 min under basal conditions (2 mM glucose), and then incubated for 45 min either
under basal (filled bars) or stimulated conditions (20 mM glucose, 10 mM forskolin, 100 mM IBMX, open bars). hGH secretion was quantified by ELISA.
The results are expressed as hGH secretion under basal and stimulatory conditions (normalized to the content) and represent the mean 6 SEM of six
independent experiments. * p,0.05 ANOVA.
doi:10.1371/journal.pone.0007770.g001
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view of these findings, the following experiments focussed on the
role of the RalA isoform.
Recently, RalA has been demonstrated to be required for the
regulation of insulin secretion [2]. To investigate the involvement
of RalA in b-cell exocytosis, INS-1E cells were transfected with a
plasmid driving the synthesis of both a small hairpin RNA
(shRNA) directed against the GTPase and of human growth
hormone (hGH) [18]. When expressed in b-cells hGH is targeted
to secretory granules and is co-released with insulin. This allowed
us to monitor exocytosis specifically in the fraction of cells
expressing the silencer. As shown in Fig. 1C, transfection of the
shRNA resulted in a decrease in the level of RalA. Western blot
quantification revealed that RalA level was reduced by about 50%
in cells expressing the RalA shRNA. Silencing of the GTPase was
accompanied with a reduction of 40% in hormone secretion
elicited by glucose and cAMP-raising agents (p,0.05, n=7)
compared to cells transfected with an empty vector or to cells
expressing a shRNA against GFP (Fig. 1D; Figure S2). Basal
secretion measured in the presence of 2 mM glucose was
unaffected. These observations are in good agreement with the
findings of Lopez et al. [2], and confirm that RalA is required to
maintain optimal secretory functions in pancreatic b-cell.
In the next set of experiments we investigated the mechanisms
leading to activation of RalA in response to different substances
capable of triggering insulin release. We initially assessed the
activation of the GTPase by capturing the activated form of RalA
on a GST-affinity column containing a fragment of Ral binding
protein 1 (RalBP1) [19]. Using this approach, we found that
incubation of MIN6 or INS-1E cells for 5 min in the presence of
20 mM glucose, 10 mM Forskolin, 100 mM IBMX and 30 mM
KCl lead to a 2–3 fold increase in the amount of RalA in the GTP-
bound form (n=3, Fig. 2A). To investigate the kinetics of RalA
activation, we then took advantage of a recently developed
Fluorescence Resonance Energy Transfer (FRET)-based probe for
RalA activity, called pRaichu-RalA [20]. The pRaichu-RalA
construct encodes a chimeric fluorescent protein that includes
from the N-terminus: a modified form of YFP, wild type RalA, the
Ral binding domain of RalBP1 and a modified form of CFP [20].
When RalA is activated, the GTPase binds to the RalBP1
fragment and triggers a conformational change in the molecule
that enables a FRET [21] between the two fluorophores, CFP and
Figure 2. Kinetics of RalA activation in response to secretagogues. A) INS-1E and MIN6 cells were first preincubated at 2 mM glucose for
30 min and then stimulated by addition of a medium containing 20 mM glucose, 30 mM KCl, 10 mM Forskolin and 100 mM IBMX. After 5 min, the
cells were lysed and the GTP-bound form of RalA isolated on GST-affinity columns. The total amount of RalA present in the cell lysates and the
fraction of the GTPase remaining associated with the beads were visualized by Western blotting. The figures show blots from a representative
experiment out of three. B) To monitor RalA activation in real-time, INS-1E cells were transfected with the pRaichu-RalA probe [20]. Two days later the
cells were first incubated at basal condition and then stimulated (arrow) with a cocktail of secretagogues including 20 mM glucose, 30 mM KCl,
10 mM Forskolin and 100 mM IBMX. RalA activation was monitored in real-time by measuring the intensity of the fluorescence at 530 and 475 nm and
by determining the changes in the FRET ratio (530 nm/475 nm emissions). The upper images show the evolution of the FRET ratio in a group of cells
after the addition of the secretagogues. Image a: 0 min; Image b: 10 min; Image c: 15 min. The lower panel shows the curve corresponding to the
kinetics of RalA activation in the cell surrounded by the square.
doi:10.1371/journal.pone.0007770.g002
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construct the activation of RalA can be monitored in real-time by
analysing the ratio between the emissions of YFP and CFP. The
probe displayed a subcellular distribution analogous to that of
GFP-tagged RalA (Figure S3). The chimeric construct was
detectable throughout the cytoplasm but was particularly abun-
dant near the plasma membrane region. As shown in Fig. 2B,
incubation of the cells in the presence of the cocktail of
secretagogues including 20 mM glucose, 10 mM Forskolin,
100 mM IBMX and 30 mM KCl led to a strong rise in the FRET
ratio. The increase in FRET was detectable after a lag of 3–5 min
and reached a plateau between 10–15 min. The activation of
RalA observed in the presence of the secretagogues was reduced
by more than 80% by the L-type voltage-gated Ca
2+-channel
blocker Nifedipine (10 mM), suggesting that the activation of the
GTPase necessitates an increase in [Ca
2+]i (Fig. 3). In agreement
with this hypothesis, a rise in [Ca
2+]i elicited by incubation of INS-
1E cells with depolarizing K
+ concentrations (30 mM) or with the
Ca
2+ ionophore Ionomycin (1 mM) resulted in a comparable
activation of RalA (Fig. 3). Part of the effect of the secretagogues
may also be linked to a rise in cAMP levels. Indeed, the activation
of RalA was diminished by approximately 80% by treatment of
the cells with the protein kinase A inhibitor H89 (10 mM).
Moreover, it was possible to activate the GTPase with the cAMP-
raising agents Forskolin (10 mM) and IBMX (100 mM) even in the
presence of low glucose concentrations (Fig. 3).
The next set of experiments aimed at determining the
mechanisms through which RalA controls insulin exocytosis. Ral
GTPases are thought to participate to vesicle docking by
modulating the assembly of the exocyst complex [12]. To assess
whether RalA is necessary for the docking of insulin-containing
granules, INS-1E cells were transfected with a plasmid encoding
fluorescently labelled Islet Amyloid Precursor Protein (IAPP-
EGFP). This protein is targeted to insulin-containing granules and
can be used to visualize the secretory vesicles of b-cells [22]. To
determine the number of secretory granules docked at the plasma
membrane, IAPP-EGFP-transfected cells were inspected by total
internal reflection fluorescence (TIRF) illumination [23]. Using this
technique, only fluorescently labelled vesicles located within about
90 nm from the plasma membrane are detected [24,25,26]. We
found that silencing of RalA reduced the number of docked
granules by about 22% (n=24 cells, control; n=40 cells. shRalA;
*p,0.05) (Fig. 4A). This effect could not be ascribed to a reduced
overall number of granules in the presence of shRalA because
the total IAPP-EGFP fluorescence/cell under epifluorescence
illumination was identical in shRalA expressing cells and in
control conditions (control cells: 141.664.31, n=45; shRalA
140.31765.17, n=45; Sec8-DN; 132.3568.34, n=18). The effect
of shRNA against RalA on docking of insulin-containing granules
was confirmed using a shRNA against GFP as a second control
(Figure S2). Interestingly, the impact of RalA knockdown on
granule docking was comparable to the effect obtained after
transfection of INS-1E cells with a dominant-negative truncated
form of the exocyst component Sec8 (n=22 cells, control; n=29
cells, Sec8-DN;*p ,0.05, Fig. 4B), a construct that has previously
beenshown toinhibit granuledocking andexocytosis inb-cells[14].
The N-terminal domain of RalA can bind and activate PLD1, a
key player in the final events leading to insulin exocytosis [17,18].
To determine the contribution of RalA to PLD1 activation in b-
cells, we measured the PLD activity in INS-1E cells upon silencing
of the GTPase. We found that basal activity that is mainly
contributed by PLD2 was unaffected. In contrast, secretagogue-
induced PLD activation that reflects PLD1 activity was strongly
reduced in cells lacking RalA (Fig. 5) (n=3, * p,0.05). The effect
of RalA silencing was comparable to the decrease in PLD activity
observed after silencing of PLD1 by RNAi [18]. Taken together,
these observations indicate that the control of PLD1 activation
constitutes an additional mechanism through which RalA can
modulate the secretory process of b-cells.
Activation of Ral proteins occurs via interaction with guanine
nucleotide exchange factors (GEFs), which promote replacement of
GDP for GTP [5,6]. The GDP/GTP exchange factor RalGDS has
recently been shown to activate Ral proteins in response to [Ca
2+]i
and cAMP elevations in endothelial cells [27]. This exchange factor
was found to be expressed both in MIN6 and INS-1E cells (Fig. 6A).
ToinvestigatethepossibleinvolvementofRalGDSintheregulation
of RalA activity in b-cell, we first generated a plasmid encoding a
shRNA specifically directed against RalGDS (shRalGDS1). We
found that, when introduced in INS-1E cells, the silencer led to a
strong decrease of RalGDS mRNA (Figure S4) and reduced by
about 60% the expression of the endogenous RalGDS protein
(Fig. 6B). The impact of RalGDS silencing on RalA activation was
then investigated by FRET analysis. RalA activation triggered by
secretagogues was found to be severely impaired in INS-1E cells co-
transfected with pRaichu-RalA and shRalGDS1 (Fig. 6C and D).
Analogous results were obtained when the activation of RalA was
assessed using GST-Pull down experiments (not shown). We then
tested the effect of RalGDS silencing on secretagogue-induced
hormone release (Fig. 7A). Our results show that hormone secretion
is diminished by more than 30% in cells lacking the exchange factor
(p,0.05, n=3), whereas overexpression of RalGDS did not further
increase hormonerelease.Thiseffect on secretion wasaccompanied
with a 24% decrease in the number of granules docked at the
plasma membrane, a reduction comparable to that obtained upon
Figure 3. RalA activation is triggered by increases in [Ca
2+]i and
cAMP. The signaling pathways leading to RalA activation were
explored by transfecting INS-1E cells with the pRaichu-RalA probe
[20] and by analyzing the fluorescence emissions at 530 nm and
475 nm. The results are expressed as maximum changes in the 530 nm/
475 nm ratio (DF) divided by the value of the ratio at the beginning of
the experiment (F0). The cells were stimulated with a combination of
secretagogues (Cocktail) containing 20 mM glucose, 30 mM KCl, 10 mM
Forskolin and 100 mM IBMX (n=11 cells), with 30 mM KCl (n=6 cells),
with 1 mM of Ionomycin (n=9 cells) or with 10 mM Forskolin and
100 mM IBMX (n=9 cells). Where indicated the cells treated with the
cocktail of secretagogues were preincubated for 15 min with 10 mMo f
the voltage-gated Ca
2+ channel blocker Nifedipine (n=9 cells) or with
10 mM of the PKA inhibitor H89 (n=6 cells). A group of cells stimulated
with 30 mM KCl were also treated with 10 mM Nifedipine (n=6 cells).
* Denotes the conditions significantly different (p,0.05 ANOVA test)
from the respective controls.
doi:10.1371/journal.pone.0007770.g003
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different shRNA (shRalGDS2) directed against RalGDS (Figure S4,
S5 and S6). Together, these findings indicate that RalGDS plays a
major role in RalA activation in response to insulin secretagogues.
Discussion
Ral GTPases are multifunctional proteins that regulate a variety
of cellular processes including oncogenic transformation, cell
proliferation and vesicular trafficking [3,4]. Although RalA and
RalB share about 85% of their amino acid sequences the functions
of the two isoforms are only partially overlapping. Indeed, RalA
and RalB have antagonistic effects on cancer cell migration [28]
and RalA but not RalB drives delivery of membrane proteins to
the basolateral surface of epithelial cells [29]. Here, we found that
RalA is the predominant isoform expressed in insulin-secreting cell
lines and in pancreatic islets of different species. Low levels of RalB
were detected in insulinoma cell lines but not in freshly isolated
pancreatic islets and may be the consequence of oncogenic
transformation. For this reason, in this study the function of RalB
was not investigated and for the moment the role, if any, of this
isoform in b-cells remains unsettled.
Ral GTPases are involved in the regulation of exocytosis in
different cell systems [4]. Recently, RalA was found to be an
important modulator of the secretory process of pancreatic b-cells
[2]. Here, we have first confirmed the involvement of RalA in
insulin exocytosis and we have then investigated the signalling
cascades leading to the activation of the GTPase and the
mechanisms through which it controls hormone release. We have
monitored RalA activation in the presence of insulin secretagogues
using imaging techniques that allow a good spatio-temporal
resolution of the generation of the active form of the GTPase. The
appearance of the GTP-bound form of RalA started few minutes
after the addition of the stimuli and peaked in about 10–15
minutes, consistent with the time course of insulin exocytosis.
Under our experimental conditions we did not observe preferential
activation of RalA in specific subcellular compartments. This
could be the consequence of the type of stimuli used in this study
and spatial differences may possibly be observed upon incubation
with agonists that lead to second messenger generation in
restricted areas of the cells.
Two second messenger cascades were found to contribute to
RalA activation: one triggered by an increase in [Ca
2+]i, resulting
from entry of the ion through L-type voltage-gated Ca
2+ channels,
and the other by elevation of cAMP. Activation of RalA via these
signalling pathways has been reported in other cell types [27]. The
stimulatory effect of Ca
2+ could potentially be mediated through
direct interaction of Ca
2+/CaM to the C-terminus of RalA [8,30]
Figure 4. Effect of RalA silencing on insulin granule docking. A) Experiments were performed under TIRF illumination. INS-1E cells were co-
transfected with a plasmid encoding IAPP-EGFP (a fluorescently labeled protein targeted to insulin granules) and either an empty vector (control) or
shRalA. On the left: representative TIRF images of control and shRalA transfected cells. On the right: histograms depict the number of granules/mm
2
counted in the ‘‘footprint’’ of each cell using TIRF illumination in control conditions and in cells transfected with shRalA. Results are the means 6 SEM
(n=23 cells control; n=40 cells shRalA). * p,0.05 one way ANOVA. Scale bar: 12 mm B) INS-1E cells were co-transfected with a plasmid encoding NPY-
mRFP (a fluorescently labeled protein targeted to insulin granules) and either an empty vector (control) or a plasmid driving the expression of a
dominant-negative form of Sec8 (Sec8-DN). Quantitative PCR analysis confirmed that in transfected cells the dominant-negative transcript was
approximately 1000-folds more abundant than the endogenous Sec8 mRNA. On the left: representative TIRF images of control andSec8-DNtransfected
cells. On the right: histograms represent number of granules/mm
2 counted in the ‘‘footprint’’ of each cell under TIRF illumination in control conditions
and in cells transfected with DSec8. Results are mean 6 SEM (n=22 cells control; n=29 cells, Sec8-DN). * p,0.05 one-way ANOVA. Scale bar: 12 mm.
doi:10.1371/journal.pone.0007770.g004
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2+/CaM to RalGDS with a
consequent stimulation of the exchange factor function [27].
RNAi experiments performed in INS-1E cells revealed that
silencing of RalGDS lead to an almost complete blockade of
RalA activation, suggesting that in b-cells the elevation of [Ca
2+]i
stimulates the GTPase mainly via the second mechanism. The
generation of cAMP in pancreatic b-cells triggers two parallel
signalling pathways regulating insulin exocytosis: one involving
PKA activation and the other the activation of Epac2 (Exchange
proteins directly activated by cAMP 2) [31]. We found that the
appearance of the GTP-bound form of RalA is prevented in INS-
1E cells treated with H89, indicating that activation of RalA
occurs via the PKA-dependent pathway. Interestingly, RalGDS is
known to be phosphorylated and activated by PKA. Thus, the
exchange factor RalGDS that is positioned at the ‘‘crossroad’’ of
the two signalling pathways appears to be the central regulator of
RalA function in b-cells.
The goal of the next series of experiments was to determine the
precise mechanism(s) through which RalA can modulate the
secretory process of b-cells. Ral GTPases have been shown to
control the association of the components of the exocyst [10,11].
This octameric protein complex is required for exocytosis by
tethering vesicles to specific sites at the plasma membrane before
the formation of the SNARE fusion complex [12]. In pancreatic b-
cells, impairment in the assembly of the exocyst results in a
decrease in the number of secretory granules docked at the plasma
membrane and in defective insulin release [14]. We found that
silencing of RalA in INS-1E cells lead to a reduction in the
number of granules docked at the plasma membrane. The impact
of RalA knockdown on granule docking was comparable to that
obtained after introduction of a dominant negative Sec mutant
that prevents the assembly of the exocyst complex [14]. These
observations suggest that part of the effect of RalA on b-cell
exocytosis may be exerted through the regulation of the assembly
of the exocyst components. Using an electron microscopy
approach, no significant changes were detected in the number of
docked granules in PC12 cells lacking both RalA and RalB [32].
At present, it is unclear whether the discrepancy between our
findings and the results of this study resides in peculiar differences
in the two cell systems or in the sensitivity of the techniques used to
determine the number of docked granules.
A relatively limited decrease in the pool of granules docked at
the plasma membrane is not necessarily associated with a defect in
exocytosis. We therefore investigated whether RalA is also
involved in the control of other important steps of the secretory
pathway. We have previously demonstrated that in chromaffin
and PC12 cells RalA is necessary for the activation of PLD1
together with the GTPase ARF6 [16]. This phospholipase plays an
essential role in insulin exocytosis by catalysing the formation of
the fusogenic lipid phosphatidic acid [17,18]. Interestingly, ARF6
was also shown to play an important regulatory function in insulin
release [33]. Here, we show that the burst in PLD1 activity
triggered by insulin secretagogues is strongly reduced in INS-1E
cells lacking RalA. These observations identify the modulation of
an ARF6-dependent PLD1 activity as an additional mechanism
through which RalA can control insulin exocytosis.
In this study, we have dissected the signalling cascades leading
to RalA activation in pancreatic b-cells and we have demonstrated
the involvement of this GTPase in two distal steps of the insulin
secretory pathway. RalA is a multifunctional protein that via its
large number of interacting partners controls other cellular events
potentially affecting the execution of the secretory process. Thus,
the capacity of RalA to influence the dynamics of the actin
cytoskeleton and to modulate endocytosis could constitute
additional means to finely tune insulin secretion. Future
experiments will have to assess whether the control exerted by
RalA on the secretory process of b-cells extends beyond the
mechanisms identified in this study. Moreover, in addition to its
role in the regulation of insulin release it will be important to
define the possible involvement of RalA in other b-cell functions
that when deregulated favour the development of diabetes mellitus
such as apoptosis or proliferation.
Materials and Methods
Ethics statement
Rat and mouse islets were isolated by hand-picking after
collagenase digestion of pancreas as described [36]. The isolation
protocol was approved by the animal care committee of the
Veterinary Office of Canton Vaud. Human islets were provided
through the European Consortium for Islet Transplantation
(ECIT), supported by JDRF grant Nu 31-2008-416. The use of
human islets for research was approved by the Geneva local
institutional ethical committee.
Cell culture
The rat INS-1E insulinoma cell line [34] was cultured in RPMI
1640 supplemented with 10% fetal calf serum, 70 mM b-
Mercaptoethanol, 50 units/ml penicillin, 50 mg/ml streptomycin
and 0.1 mM sodium pyruvate. Mouse MIN6B1 insulinoma cells
[35] were grown in Dulbecco’s modified Eagle’s medium
supplemented with 15% fetal calf serum, 70 mM b-Mercaptoeth-
anol, 50 units/ml penicillin and 50 mg/ml streptomycin.
Plasmids and transfection
The pRaichu-RalA probe [20] used for FRET imaging was
generously provided by Dr. M. Matsuda, Kyoto University, Japan.
The mammalian expression vector encoding mouse RalGDS was
Figure 5. Effect of RalA silencing on PLD activity. INS-1E cells
were transfected with an empty vector (Control), with a plasmid
encoding a shRNA directed against GFP (shGFP), RalA (shRalA) or PLD1
(shPLD1) [18]. Three days later the cells were incubated under basal
conditions in a medium containing 2 mM glucose or were stimulated
during 10 min with 20 mM glucose, 30 mM KCl, 10 mM Forskolin and
100 mM IBMX. At the end of the incubation period, cell lysates were
prepared and assayed for PLD activity. Histograms show PLD activity
(mU/50 mg of proteins) measured under basal and stimulatory
conditions. The results are the means 6 SD of three independent
experiments. * p,0.05, one-way ANOVA.
doi:10.1371/journal.pone.0007770.g005
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Germany. The plasmid encoding EGFP-tagged N-terminally
truncated Sec8 (pIRES2- Sec8-DN, called here Sec8-DN) was
obtained from Dr. G. Rutter, Imperial College of London, UK.
The shRNA against rat RalA (shRalA) and the two shRNAs
against rat RalGDS (shRalGDS1 and shRalGDS2), targeting the
nucleotide sequences AAGGCAGGTTTCTGTAGAA, GCCA-
TGGACAAACACAACC and CTCTGCCGCCAACTATGAC,
respectively, were prepared by inserting the corresponding
oligonucleotides in the Hind III/Bgl II sites of a modified pSuper
vector engineered to express the human Growth Hormone (hGH)
[16]. The shRNA against PLD1 has been described previously
[18]. Control cells were either transfected with an empty plasmid
or with a pSuper plasmid expressing a shRNA targeting the GFP
sequence GGCTACGTCCAGGAGCGCA (shGFP). Transient
transfection experiments were performed as described [37] using
Lipofectamine 2000 (Invitrogen. Carlsbad, CA). Under our
experimental conditions, the transfection efficiency evaluated by
fluorescence activated cell sorting of EGFP-transfected cells is
about 55%.
Immunoblotting
INS-1E cells, MIN6B1 cells or purified pancreatic islets were
resuspended in PBS and briefly sonicated. The homogenates were
centrifuged at 4uC for 1 minute at 10’000 x g to pellet nuclei and
cell debris. 30 mg of proteins collected in the supernatant were
separated by SDS-PAGE, transferred to nitrocellulose membranes
and detected using specific antibodies. The RalA antibody was
obtained from BD Transductions Laboratories (Lexington, KY),
RalB and RalGDS antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA) and the b-actin antibody from
Sigma (St. Louis, MO). Visualization of the immunocomplexes
was performed by chemiluminescence (Amersham Biosciences,
Piscataway, NJ) after incubation of the nitrocellulose membranes
with secondary antibodies coupled to horse radish peroxidase.
RT-PCR Analysis
Total RNA was prepared using the Ambion’s RNA extraction
kit (Austin, TX). Reverse transcription reactions were performed
as previously described [38]. For RalA and RalB mRNA
expression studies 30 amplification cycles were carried out in the
presence of the following primers: RalA sense, 59-ACAAGCC-
CAAGGGTCAGAAT-39; antisense, 39-ACTGCCCACCATGA-
TGACTT-59; RalB sense, 59-GGCCATCCGTGACAACTACT-
39; antisense, 39-GAGAACACCAGCAGAAAGC-59. RalGDS
and Sec8 mRNA levels were assessed by quantitative real-time
PCR (qRT-PCR) analysis carried out on a BioRad MyIQ Single-
Color Real-Time PCR detection system using the following
primers: RalGDS sense, 59-ACTCCCTGAGCAGAGAGCTG-
39; RalGDS antisense, 39-GGGCTCTCCTAGGGTTCATC-59;
Sec8 sense, 59-GCCGAACAAAGTCAGCTTTC-39; Sec8 anti-
sense, 59-CACTTCCAGATGCAAGACGA-39. Normalization of
Figure 6. Silencing of RalGDS prevents the activation of RalA. A) Expression of RalGDS in INS-1E and MIN6 cells assessed by Western Blotting.
B) The efficiency of a shRNA directed against RalGDS (shRalGDS1) was verified by transiently co-transfecting INS-1E cells with the shRNA-expressing
vector. The level of the exchange factor was analyzed two days later by Western blotting. The figure shows a representative experiment out of three.
C) To observe the effect of RalGDS knockdown on RalA activation, INS-1E cells were co-transfected with pRaichu-RalA and either an empty vector
(filled squares) or with shRalGDS1 (open squares). Two days later, the cells were stimulated (arrow) with a cocktail of secretagogues containing
20 mM glucose, 30 mM KCl, 10 mM Forskolin and 100 mM IBMX and RalA activity was followed in real-time. The figure shows a representative
experiment with the mean 6 SD of the variations in the 530 nm/475 nm ratio of three control cells and three cells transfected with shRalGDS1. D)
Quantification of RalA activation was performed by monitoring the variations between the fluorescence at 530 nm and 475 nm in cells transfected
with an empty vector (Control) and cells expressing shRalGDS1. The results are expressed as maximum changes in the 530 nm/475 nm ratio (DF)
divided by the value of the ratio at the beginning of the experiment (F0) 6 SD (Control, n=7 cells; shRalGDS, n=10 cells). * p,0.05 ANOVA.
doi:10.1371/journal.pone.0007770.g006
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mRNA levels with the following primers: GAPDH sense, 59-T-
CCATGACAACTTTGGCATTG-39; GAPDH antisense, 59CA-
GTCTTCTGGGTGGCAGTGA-39.
Secretion assay
Secretion experiments in INS-1E cells were performed three
days after transfection. The cells were washed and then
preincubated in a KREBS-Ringer/bicarbonate-Hepes buffer
(KRBH: 127 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4,
1.2 mM MgSO4, 1 mM CaCl2, 5 mM NaHCO3, 25 mM Hepes
pH 7.4 and 0.1% bovine serum albumin) containing 2 mM
glucose. After 30 min at 37uC, the buffer was discarded and the
cells incubated either again in KRBH containing 2 mM glucose
(basal condition) or with KRBH containing 20 mM glucose and
supplemented with 10 mM Forskolin and 100 mM IBMX
(stimulatory condition). The amount of hGH released into the
medium under basal and stimulatory conditions and the fraction
of hormone remaining in the cells at the end of the incubation
period were quantified by ELISA (Roche Diagnostics, Rotkreuz,
CH).
Measurement of RalA activation using a pull-down assay
MIN6B1 or INS-1E cells cultured in 6-well plates were
preincubated at 37uC for 30 min under basal conditions (KRBH
containing 2 mM glucose). The medium was then removed and
the cells incubated for 5 min in KRBH containing 2 mM glucose
or in KRBH containing 20 mM Glucose, 10 mM Forskolin,
100 mM IBMX and 30 mM KCl. The cells were then lysed in ice
cold pull-down buffer (50 mM Tris-HCl, pH 7.5, 200 mM NaCl,
1% NP-40, 10 mM MgCl2, 0.5 mM dithiothreitol, 1 mM PMSF
and 10 mg aprotinin). The lysates were cleared by spinning at top
speed for 10 min on a bench-top centrifuge and then passing
through a 0.22 mm filter. Aliquots of 250–500 mg of protein lysate
were mixed with GST-RalBP1 agarose beads (Upstate Biotech-
nology, Waltham, MA) and incubated for 30–60 min at 4uC. The
beads were washed three times in pull-down buffer and the
proteins remaining associated with the beads resuspended in
Laemmli buffer. The fraction of GTP-bound RalA recovered on
the GST-affinity column was determined by Western blotting.
Measurement of RalA activity in living cells with
Fluorescence resonance energy transfer (FRET) imaging
Real-time assessment of RalA activity was carried out by using
the Raichu-RalA probe [20]. INS-1E cells plated on glass
coverslips coated with 2 mg/ml poly-L-lysine and 33 mg/ml
laminin were co-transfected with the pRaichu-RalA probe and
with the indicated plasmids. Two days after transfection, the cells
were preincubated at low glucose for 30 min. The coverslips were
then mounted in an open perfusion incubator at 37uC on the stage
of a Zeiss Axiovert 200 fluorescence inverted microscope modified
for imaging experiments [39]. The cells were imaged through a 63
x oil immersion objective (Zeiss, Germany) at 1 min intervals with
a cooled charged-coupled device (SNAP-HQ CCD) camera.
Excitation of the samples at 433 nm was obtained with a
polychromator lamp (Visitron System, Germany). Emissions at
530 and 475 nm were collected with two cube filter sets: 51017
filter set for CFP and 41028 filter set for YFP (Omega Optical,
Brattleboro, VT). The camera and the polychromator were
controlled by the Metafluor software (Universal Imaging, Ypsilanti
MI). For analysis, the 530 and 475 nm emissions were monitored
in ROIs centered on top of each cell. After background
subtraction the FRET ratio (530/475 nm) was calculated with
Origin software (Northampton, MA).
Imaging docked granules with Total Internal
Fluorescence Reflection (TIRF) microscopy
For TIRF experiments, INS-1E cells were plated on glass
coverslips coated with 2 mg/ml poly-L-lysine and 33 mg/ml
laminin. Insulin-containing secretory granules were imaged by
transfecting the cells either with IAPP-Emerald [22] or with NPY-
mRFP [40]. Two days after transfection the cells were analysed
using a Zeiss Axiovert 200 inverted fluorescence microscope
modified to allow epifluorescence and evanescence field (TIRF)
illumination [24,25,26]. The cells were incubated under resting
conditions during the whole experiment. For TIRF illumination,
Figure 7. Knockdown of RalGDS leads to inhibition of hormone
secretion and granule docking. A) To evaluate the involvement of
RalGDS in the control of hormone secretion, INS-1E cells were co-
transfected with a plasmid encoding hGH and with an empty vector
(Control), a plasmid permitting the overexpression of RalGDS or with
shRalGDS1. Three days later the cells were incubated for 30 min at basal
conditions (2 mM glucose), and then 45 min either at basal (filled bars)
or stimulated conditions (20 mM glucose, 10 mM Forskolin and 100 mM
IBMX, open bars). Hormone release was quantified by ELISA. The
histograms represent the means 6 SEM of three independent
experiments. * Significantly different (p,0.05 ANOVA). B) INS-1E cells
were co-transfected with a plasmid encoding IAPP-EGFP and either an
empty vector (Control), shRalA or shRalGDS1. Histograms show the
number of granules/mm
2 counted in the ‘‘footprint’’ of each cell by
using TIRF illumination in control conditions and in cells transfected
with shRalA. Results are expressed as means 6 SEM (n=24 cells control;
n=36 cells shRalA; n=27 cells shRalGDS1). * p,0.025 Bonferroni test.
doi:10.1371/journal.pone.0007770.g007
Function of RalA in b-Cells
PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7770the expanded beam (488 nm–568 nm argon krypton multi-line
laser, 20 mW) was passed through an AOTF wavelength selector
synchronized with a SNAP-HQ CCD Camera under Metafluor
software control and introduced from the high numerical aperture
objective lens (100 X, 1.45 NA, Zeiss, Germany). Light entering
the coverslips underwent total internal reflection at the glass-cell
interface with a penetration depth of about 100 nm. Light were
filtered with a beam splitter (Zeiss filter set 10). Video images were
digitized and analyzed using the Metamorph software (Universal
Imaging, Ypsilanti MI). Single IAPP-Emerald or NPY-mRFP
positive granules were counted manually in single cell areas. Only
cells displaying a docking surface area of at least 100 mm
2 were
selected. Granule densities (number of docked granules per mm
2)
under the different experimental conditions were compared using
the analysis of variance (GLM procedure from SAS statistical
package, SAS Institute Inc., Cary, NC, USA), with the multiple
comparisons of means (Bonferroni post hoc test).
Measurement of PLD activity
INS-1E cells cultured in 6-well plates to about 80% confluency
were washed twice and preincubated in KRBH containing 2 mM
glucose during 30 min. The medium was then removed and the
cells were either incubated again in the same buffer or stimulated
for 10 min in KRBH containing 20 mM glucose, 10 ml Forskolin,
100 ml IBMX30 and mM KCl. At the end of the incubation
period the cells were resuspended in ice-cold Tris-HCl (50 mM,
pH 8.0) and disrupted by three freeze/thawing cycles. PLD
activity was measured in 50 mg of cell extracts using the Amplex
Red phospholipase D assay kit (Invitrogen Corporation, Carlsbad
CA) according to the manufacturer’s instructions. A standard
curve for PLD activity was obtained by incubating under the same
conditions aliquots of purified PLD from Streptomyces chromofuscus
(Sigma, St. Louis MO).
Statistical analysis
The experiments were analyzed using the SAS statistical
package (SAS Inc., Cary NC, USA). The analysis of variance
(ANOVA) procedure was used followed, when indicated, by the
Bonferroni multiple comparisons post-hoc test with a significance
limit set at p,0.05.
Supporting Information
Figure S1 Detection of Ral GTPases in INS-1E cells overex-
pressing RalA or RalB. Samples obtained from INS-1E cells
transfected with an empty vector (control) and from cells
transfected with RalA or RalB expressing plasmids were analyzed
by Western blotting using antibodies against RalA (A) or RalB (B).
Equal loading between the different lanes was assessed by
analyzing the same samples with an antibody against actin.
Found at: doi:10.1371/journal.pone.0007770.s001 (0.70 MB TIF)
Figure S2 Comparison between the effect of shRalA and of a
shRNA against GFP on hormone secretion and granule docking.
A) INS-1E cells were co-transfected with a plasmid encoding hGH
and with plasmids permitting the expression of shGFP or shRalA.
Three days later the cells were incubated for 30 min at basal
conditions (2 mM glucose), and then 45 min either at basal (filled
bars) or stimulated conditions (20 mM glucose, 10 mM Forskolin
and 100 mM IBMX, open bars). Hormone release was quantified
by ELISA. The results are the means 6 SEM of five independent
experiments. * p,0.05 ANOVA. B) INS-1E cells were co-
transfected with a plasmid encoding NPY-mRFP and either
shGFP or shRalA. The number of granules docked at the plasma
membrane per mm
2 was observed and counted by inspecting the
cells by TIRF microscopy. Silencing of RalA resulted in a
significant reduction in the number of docked granules per mm
2
(Bonferroni test: * p,0.05). Results are presented as means 6
SEM (n=23 cells, shGFP; n=22 cells, shRalA).
Found at: doi:10.1371/journal.pone.0007770.s002 (0.46 MB TIF)
Figure S3 Subcellular localization of the chimeric probe
pRaichu-RalA. INS-1E cells transfected with the pRaichu-RalA
plasmid (A) or with GFP-tagged RalA (B) were analyzed by
confocal microscopy. Notice that both fluorescent probes display a
similar subcellular distribution in the cytosolic and plasma
membrane compartments. Scale bar 25 mm.
Found at: doi:10.1371/journal.pone.0007770.s003 (1.19 MB TIF)
Figure S4 Effect of two different shRNAs on RalGDS mRNA
level. To test the silencing efficiency of two shRNAs directed
against RalGDS, total RNAs extracted from INS-1E cells
expressing shGFP, shRalGDS1 or shRalGDS2 were analyzed by
quantitative Real-Time PCR. Transfection of shRalGDS1 and
shRalGDS2 reduced RalGDS mRNA levels by 83 and 85%,
respectively. The results represent the means 6 SD of three
independent experiments. * p,0.001 ANOVA.
Found at: doi:10.1371/journal.pone.0007770.s004 (0.43 MB TIF)
Figure S5 Effect of shRalGDS 1 and 2 on RalA activation.
Quantification of RalA activation was performed by monitoring
the variations between the fluorescence at 530 nm and 475 nm
in cells transfected with shGFP, with shRalGDS1 or
shRalGDS2. The results are expressed as maximum changes
in the 530 nm/475 nm ratio (DF) divided by the value of the
ratio at the beginning of the experiment (F0) 6 SD (n=6 cells
shGFP; n=4 cells shRalGDS1; n=4 cells shRalGDS2).
*p ,0.05, ANOVA.
Found at: doi:10.1371/journal.pone.0007770.s005 (0.45 MB TIF)
Figure S6 Effect of shRalGDS 1 and 2 on hormone secretion
and insulin granule docking. A) INS-1E cells were co-transfected
with a plasmid encoding hGH and with shGFP, shRalGDS 1 or
shRalGDS 2 encoding vectors. Hormone release under basal
(filled bars) and stimulatory conditions (open bars) was assessed
three days later by ELISA. The results are means 6 SEM of six
independent experiments. * p,0.05, ANOVA. B) INS-1E cells
were co-transfected with a plasmid encoding NPY-mRFP and
either shGFP, shRalGDS1 or shRalGDS 2. The granules docked
at the plasma membrane were visualized by TIRF microscopy.
Silencing of RalGDS with shRalGDS 1 or shRalGDS 2 resulted in
a significant reduction in the number of docked granules per mm
2
(Bonferroni test: * p,0.05). The results are given as means 6
SEM (n=23 cells, shGFP; n=21 cells, shRalGDS 1; n=22 cells,
shRalGDS 2).
Found at: doi:10.1371/journal.pone.0007770.s006 (0.50 MB TIF)
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